PharmaShots | Incisive News in 3 Shots

Subscribe Now

schizophrenia

Neurocrine Signs a License Agreement with Sosei Heptares to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Neurocrine Signs a License Agreement with Sosei Heptares to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other...

November 23, 2021

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

September 2, 2021

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with S...

May 25, 2021

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...

May 19, 2021

Janssen Reports sNDA Submission of Paliperidone Palmitate 6-Month (PP6M) to the US FDA for Schizophrenia

Janssen Reports sNDA Submission of Paliperidone Palmitate 6-Month (PP6M) to the US FDA for Schizophrenia

November 3, 2020

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

September 15, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us